

# Preclinical study of JPC-089, a blood cancer treatment targeting PIM kinase

JEIL PHARMA-CEUTICAL CO.,LTD.

JEIL PHARMACEUTICAL CO.,LTD.

|                                 |  |
|---------------------------------|--|
| <b>ONCOLOGY</b>                 | <b>Non-Clinical</b>  |
| <b>Product Type</b>             | Chemical product   |
| <b>Indication</b>               | 1st indication: Acute Myeloid Leukemia(AML)<br>2nd indication: Multiple Myeloma(MM), Solid tumor(PIM kinase overexpressed)   |
| <b>Target</b>                   | pan-proviral insertion in murine(PIM) kinase   |
| <b>MoA(Mechanism of Action)</b> |  |
| <b>Competitiveness</b>          | <ul style="list-style-type: none"> <li>• Confirmation of in vitro and in vivo efficacy</li> <li>• Completed confirmation of the PIM kinase related MoA study</li> <li>• Could be applied to combined administration and chemo-resistant study</li> </ul> |
| <b>Development Stage</b>        | Non-Clinical   |
| <b>Route of Administration</b>  | Oral administration  |